Akebia Therapeutics (AKBA) Stock: Buy, Sell, or Hold?
AKBA - Akebia Therapeutics, Inc.
$0.67
-0.03 (-3.67%)
▼
5d:
-16.36%
30d:
-25.18%
90d:
-47.66%
WAIT
LOW Confidence
Analysis Updated: Oct 16, 2026 12:00 AM ET
Earnings: Nov 09, 2026
21d
Get Alerted When AKBA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: AKBA is down 16.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: AKBA is down 16.4% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: AKBA is currently trading at $0.67, which is considered oversold relative to its 30-day fair value range of $0.79 to $0.96. From a valuation perspective, the stock is trading at a discount (Forward PE: -1.9) compared to its historical average (12.4). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, AKBA is in a downtrend. The price is currently testing key support at $0.67. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: AKBA scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.92 (+484.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, AKBA is in a downtrend. The price is currently testing key support at $0.67. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.7% recently.
Market Sentiment: AKBA scores 25/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $3.92 (+484.6%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.79 -
$0.96
Company Quality Score
43/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
57.1%
Protect Your Profits
Holding AKBA? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BULLISH: Price oversold vs 30-day range
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.7%)
- BULLISH: Trading 484.6% below Wall St target ($3.92)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 42/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.79 -
$0.96
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.67
Resistance Level
$0.92
Current Trend
Downtrend
Technical data as of
Oct 16, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-1.86
Wall Street Target
$3.92
(+484.6%)
Revenue Growth (YoY)
-21.4%
Profit Margin
-13.5%
PE vs Historical
-1.9 vs 12.4
CHEAP
Share & Embed Analysis
Last updated: October 17, 2026 7:46 PM ET
Data refreshes hourly during market hours. Next update: 8:46 PM
Data refreshes hourly during market hours. Next update: 8:46 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is AKBA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
29 analysts |
$207 | 58 HOLD |
|
ALKS
Alkermes Plc |
STRONG BUY
19 analysts |
$57 | 64 BUY |
|
ELAN
Elanco Animal Health |
STRONG BUY
16 analysts |
$31 | 53 HOLD |
|
AMLX
Amylyx Pharmaceuticals I… |
STRONG BUY
12 analysts |
$42 | 55 HOLD |
|
HCM
HUTCHMED DRC |
STRONG BUY
13 analysts |
$22 | 55 HOLD |
Advanced AKBA Option Strategies
Professional options setups generated by AI based on today's AKBA price and gamma walls.
